My partner is Gleason 9, grade 5, BRCA 1. Highest PSA at diagnosis and prostatectomy was 2.67. Started on Lupron right away. Abi and pred started when PSA went to .26 a year after surgery.
We’re in Florida for a few months and went to Moffit for a second opinion. Doctor took him off abi and pred right away (he’d been on for 2 months). He said with low producing PSA cancer the risk of it flipping to neuroendocrine cancer is high so you don’t want to throw a lot of drugs at it right away.
Does this sound correct?
Written by
Sparkler1
To view profiles and participate in discussions please or .
Treatment-emergent NEPC has not been reported in mHSPC, and is not a reason to avoid hormone therapy. Low PSA subtypes respond well to intensive hormone therapy. Here's what Rahul Aggarwal said:
"“Although long term androgen deprivation therapy may be associated with the development of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in a minority of patients, multiple studies have confirmed the long-term benefit of abiraterone and enzalutamide for prostate cancer patients in various disease settings. Use of these agents should not be limited by concern for the subsequent development of t-SCNC.”
You may want to get a second opinion from Rahul Aggarwal at UCSF.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.